CombiMatrix Corporation Release: Author of Nationwide, National Institutes of Health (NIH)-Sponsored Study Endorses Microarray Testing as Preferred Standard of Care for Pre-Natal Testing

IRVINE, Calif., Feb. 13, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, today announced that one of the nation's leading clinicians in the field of reproductive genetics has called for chromosomal microarray testing to replace karyotyping, the historic practice, as the standard of care for prenatal testing. CombiMatrix is one of the few independent companies that specialize in chromosomal microarray testing (CMA), the primary genetic test to evaluate newborns with birth defects but has not routinely been used for prenatal testing.

Back to news